USC Roski Eye Institute
Welcome,         Profile    Billing    Logout  
 1 Trial 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chang, Jessica
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Kossler, Andrea
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Recruiting
3
143
Europe, US
Intervention/Treatment
Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/25
03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)

Active, not recruiting
3
188
Europe, US, RoW
Veligrotug (VRDN-001), Placebo
Viridian Therapeutics, Inc.
Thyroid Eye Disease
12/24
09/25
Randleman, J Bradley
NCT03115710: The K-Map Study, Global Prevalence of KC

Recruiting
N/A
700
US, RoW
Rotating Scheimpflug camera (Pentacam HR)
University Hospital, Geneva, ELZA Institute
Keratoconus
02/25
02/25
Kashani, Amir H
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
NCT05809596: HEAL-LAA Clinical Trial

Active, not recruiting
N/A
949
US
WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure
Boston Scientific Corporation
Atrial Fibrillation, Bleeding, Stroke
07/24
08/25
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
OCTA-RVD, NCT04505618: Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Recruiting
N/A
1050
US
Swept-Source (SS) OCT Angiography, SS-OCTA, Spectral-Domain (SD) OCT Angiography, SD_OCTA, Fundus Imaging, Axial Length Measurement Device, Intraocular Lens (IOL) Master
Johns Hopkins University, National Eye Institute (NEI)
Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential, Retinal Vascular Disorder
06/25
09/25
Zhang-Nunes, Sandy
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
NCT06174064: BroadBand Light for the Treatment of Dry Eye Disease

Not yet recruiting
N/A
60
NA
Broadband Light treatment, Intense Pulsed Light, Sham broadband light treatment
University of Southern California, Ophthalmic Surgeons & Consultants of Ohio, Inc.
Dry Eye Syndromes, Meibomian Gland Dysfunction
07/25
08/25
Xu, Benjamin
The XU Study, NCT05835141: Rates and Risk Factors of Contact Between the OTX-TIC Intracameral Ocular Implant and Corneal Endothelium

Recruiting
N/A
100
US
OCT Imaging
University of Southern California
Corneal Endothelium
01/24
05/24
Zhang, Sandy X
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Angell, Trevor E
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Gokoffski, Kimberly K
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Ameri, Hossein
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting
N/A
1500
Europe, Canada, US, RoW
Jaeb Center for Health Research, Foundation Fighting Blindness
Inherited Retinal Degeneration, Retinitis Pigmentosa
12/28
12/28
Leibowitz, Steven
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Recruiting
3
143
Europe, US
Intervention/Treatment
Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/25
03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)

Active, not recruiting
3
188
Europe, US, RoW
Veligrotug (VRDN-001), Placebo
Viridian Therapeutics, Inc.
Thyroid Eye Disease
12/24
09/25
Jain, Amy Patel
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Recruiting
3
143
Europe, US
Intervention/Treatment
Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/25
03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)

Active, not recruiting
3
188
Europe, US, RoW
Veligrotug (VRDN-001), Placebo
Viridian Therapeutics, Inc.
Thyroid Eye Disease
12/24
09/25

Download Options